top of page
logo_3 (2).png

Xeptiva therapeutics raises $2.5m seed to TRANSFORM pet healthcare with therapeutics vaccines

OCTOBER 1, 2024

xeptiva-66-2.jpg
​The fundraising comes at a crucial time for the company, which has achieved significant milestones, including the production of its first batch of Xep01, its osteoarthritis treatment, and the completion of pilot studies for its key developing products. This brings us closer to market readiness.
​
The support from our investors reflects their confidence in our mission and the disruptive potential of our solutions in the animal health sector. 

Xeptiva is on track to complete clinical trials and aims to secure regulatory approval for its products in 2026. As the pet care market continues to grow, we are committed to being pioneers in the next generation of veterinary therapeutics.
Xeptiva Therapeutics is pleased to announce the successful closure of a $2.5 million seed funding round, led by Zentynel Frontier Investments, with participation from iThink VC, ND Latam, Sergio Fogel, FEN Ventures, and Uruguay Biotech Ventures. This funding will enable Xeptiva to advance its mission of revolutionizing pet healthcare through innovative therapeutic vaccines targeting chronic conditions.
​
With a focus on improving the quality of life and extending the lifespan of animals, Xeptiva is developing two key products: a therapy for chronic osteoarthritis pain and another for atopic dermatitis in dogs, both currently in clinical trial phases.
Xeptiva is targeting a significant market, estimated at $5 billion, addressing the most prevalent chronic conditions in pets. Our approach offers a viable alternative to existing treatments, which are often costly and limited in their effectiveness. 
bottom of page